We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
-8.57%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$3.15B
AUM Growth
+$16.9M
Cap. Flow
-$33.7M
Cap. Flow %
-1.07%
Top 10 Hldgs %
42.21%
Holding
106
New
27
Increased
26
Reduced
18
Closed
18

Top Buys

Rank Stock Value
1
DFPHU
DFP Healthcare Acquisitions Corp. Unit
DFPHU
+$103M
2
VTRS icon
Viatris
VTRS
+$76.6M
3
PCRX icon
Pacira BioSciences
PCRX
+$67.6M
4
BKD icon
Brookdale Senior Living
BKD
+$65.1M
5
ABMD
Abiomed Inc
ABMD
+$62.4M

Top Sells

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$79.8M
2
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$71.3M
3
TNDM icon
Tandem Diabetes Care
TNDM
+$66.5M
4
HUM icon
Humana
HUM
+$30.1M
5
BOLD
Audentes Therapeutics, Inc
BOLD
+$29.6M

Sector Composition

Rank Sector Weight
1 Healthcare 71.83%
2 Technology 0.07%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FTSV
51
DELISTED
Forty Seven, Inc. Common Stock
FTSV
$14.8M 0.47%
155,380
-291,620
-65% -$17.6M
UHS icon
52
Universal Health Services
UHS
$10.1B
$13.8M 0.44%
+138,874
New +$17.6M
BDTX icon
53
Black Diamond Therapeutics
BDTX
$101M
$13.4M 0.42%
+536,001
New +$16.3M
PASG icon
54
Passage Bio
PASG
$14.7M
$10.6M 0.34%
+33,518
New +$10.5M
VAPO
55
DELISTED
Vapotherm, Inc. Common Stock
VAPO
$10.5M 0.33%
+69,591
New +$6.28M
CERS icon
56
Cerus
CERS
$585M
$10.3M 0.33%
+2,204,700
New +$9.99M
TARA icon
57
Protara Therapeutics
TARA
$221M
$9.95M 0.32%
432,670
+381,945
+753% +$11.1M
AXGN icon
58
Axogen
AXGN
$2.19B
$9.76M 0.31%
+937,983
New +$11.9M
CABA icon
59
Cabaletta Bio
CABA
$445M
$9.38M 0.3%
1,284,313
-344,191
-21% -$4.72M
BCRX icon
60
BioCryst Pharmaceuticals
BCRX
$2.48B
$9.31M 0.3%
4,652,926
-1,722,217
-27% -$4.74M
APLT
61
DELISTED
Applied Therapeutics
APLT
$9.1M 0.29%
+278,359
New +$11.3M
SIEN
62
DELISTED
Sientra, Inc.
SIEN
$8.41M 0.27%
422,768
– –
PBYI icon
63
Puma Biotechnology
PBYI
$406M
$8.13M 0.26%
963,212
+566,740
+143% +$5.51M
ELVN icon
64
Enliven Therapeutics
ELVN
$3.84B
$8.02M 0.25%
+125,000
New +$7.96M
MNK
65
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$7.97M 0.25%
4,026,750
– –
LUMO
66
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$7.96M 0.25%
+936,169
New +$13.1M
ISEE
67
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$7.8M 0.25%
2,267,409
+1,267,409
+127% +$7.41M
SYRS
68
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$7.53M 0.24%
126,895
– –
XERS icon
69
Xeris Biopharma Holdings
XERS
$1.42B
$6.7M 0.21%
3,433,291
+850,000
+33% +$3.66M
ITMR
70
DELISTED
Itamar Medical Ltd. American Depository Shares
ITMR
$5.88M 0.19%
499,136
+185,000
+59% +$2.52M
STIM icon
71
Neuronetics
STIM
$130M
$2.98M 0.09%
1,575,000
+500,000
+47% +$1.56M
CHNG
72
DELISTED
Change Healthcare Inc. Common Stock
CHNG
$2.15M 0.07%
+214,789
New +$3M
HARP
73
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$1.94M 0.06%
+16,764
New +$2.36M
OXFD
74
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$1.43M 0.05%
+154,396
New +$2.16M
TPST icon
75
Tempest Therapeutics
TPST
$13.9M
$892K 0.03%
+866
New +$1.26M
1 2
3
4

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q1 2020 Portfolio in Review

As of Q1 2020, Deerfield Management held 106 positions worth $3.15B, up 0.54% from $3.13B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Deerfield Management's Q1 2020 filing shows 27 new, 26 increased, 18 reduced and 18 closed positions. Its largest new stake was DFP Healthcare Acquisitions Corp. Unit: 10,460,000 shares worth $103M. The largest sale was Acceleron Pharma, an estimated $79.8M.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, down from 78% a quarter earlier, followed by Technology and Financials.

  • Deerfield Management's largest Q1 2020 buy was DFP Healthcare Acquisitions Corp. Unit: 10,460,000 shares worth $103M.
  • Deerfield Management added most to Viatris in Q1 2020, an estimated $76.6M increase.
  • Deerfield Management's biggest Q1 2020 reduction was Acceleron Pharma, cutting an estimated $79.8M.
  • Deerfield Management fully exited Ra Pharmaceuticals, Inc. Common Stock in Q1 2020, selling an estimated $71.3M.
  • Deerfield Management's ten largest holdings make up 42% of its $3.15B portfolio in Q1 2020.
  • Deerfield Management opened 27 new positions and closed 18 in Q1 2020.
  • Deerfield Management's portfolio value rose 0.54% quarter-over-quarter to $3.15B.

Based on Deerfield Management's 13F filing for Q1 2020, filed 15 May 2020.